Work

Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome

Year: 2023

Type: article

Abstract: Reactive granulomatous dermatitis (RGD) may occur in response to a variety of underlying etiologies, including autoimmune conditions, medications, and malignancy. Rarely, RGD may be a presenting sign of myelodysplastic syndrome or myeloid leukemia, and recognition of this cutaneous manifestation is essential so that patients can be evaluated and treated accordingly.1 The treatment of RGD centers around managing the underlying condition, although other treatments, including topical/oral corticosteroids, hydroxychloroquine, tetracycline antibiotics, methotrexate, cyclosporine, dapsone, and tumor necrosis factor-α inhibitors have been utilized with varying efficacy.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2023.08.009

Authors: Christina Huang, Adar Berghoff, Jack L. Arbiser

Institution: Thomas Jefferson University

Language: English

Topic: Autoimmune and Inflammatory Disorders

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $675